Database : MEDLINE
Search on : fungemia [Words]
References found : 3732 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 374 go to page                         

  1 / 3732 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29505004
[Au] Autor:Yu X; Cai X; Xu X; Zhang L; Huang X; Wang L; Chen Y
[Ad] Address:Division of Pulmonary Medicine, The People's Hospital of Cangnan, Wenzhou Medical University, Cangnan.
[Ti] Title:Fungemia caused by Penicillium marneffei in an immunocompetent patient with COPD: A unique case report.
[So] Source:Medicine (Baltimore);97(3):e9658, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: This report describes a rare case in Wenzhou city of Zhejiang province that a non-HIV infected male recovering from fungemia caused by Penicillium marneffei (P. marneffei). Interestingly, it's very easy to misdiagnose with aspergillosis, a fungal disease prevalent in Wenzhou, during the whole procedure. PATIENT CONCERNS: An 80-year-old Chinese male subject with pre-existing chronic obstructive pulmonary disease (COPD) presented with symptoms of chest tightness and high fever for a month. DIAGNOSES: Fungal culture from the blood isolated P marneffei. Naturally, the patient was diagnosed with P marneffei fungemia. However, he was proven serologically to be negative for human immunodeficiency virus (HIV). INTERVENTIONS: The patient was treated with voriconazole at 200mg/dL every 12 hours via intravenous administration. OUTCOMES: The fever returned to normal and chest tightness disappeared gradually after a week of voriconazole treatment. LESSONS: A high level of clinical suspicion and awareness is necessary for early diagnosis of P marneffei fungemia, especially in elder patients with underlying diseases.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process
[do] DOI:10.1097/MD.0000000000009658

  2 / 3732 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Clinical Trials Registry
Full text

[PMID]: 29347874
[Au] Autor:Venkatesh B; Finfer S; Cohen J; Rajbhandari D; Arabi Y; Bellomo R; Billot L; Correa M; Glass P; Harward M; Joyce C; Li Q; McArthur C; Perner A; Rhodes A; Thompson K; Webb S; Myburgh J; ADRENAL Trial Investigators and the Australian­New Zealand Intensive Care Society Clinical Trials Group
[Ad] Address:From the George Institute for Global Health, University of New South Wales (B.V., S.F., D.R., L.B., M.C., P.G., M.H., Q.L., K.T., J.M.), St. George Clinical School, St. George Hospital (J.M.), Sydney Medical School, University of Sydney (B.V., S.F., J.M.), and Royal North Shore Hospital (S.F.), Sydn
[Ti] Title:Adjunctive Glucocorticoid Therapy in Patients with Septic Shock.
[So] Source:N Engl J Med;378(9):797-808, 2018 03 01.
[Is] ISSN:1533-4406
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Whether hydrocortisone reduces mortality among patients with septic shock is unclear. METHODS: We randomly assigned patients with septic shock who were undergoing mechanical ventilation to receive hydrocortisone (at a dose of 200 mg per day) or placebo for 7 days or until death or discharge from the intensive care unit (ICU), whichever came first. The primary outcome was death from any cause at 90 days. RESULTS: From March 2013 through April 2017, a total of 3800 patients underwent randomization. Status with respect to the primary outcome was ascertained in 3658 patients (1832 of whom had been assigned to the hydrocortisone group and 1826 to the placebo group). At 90 days, 511 patients (27.9%) in the hydrocortisone group and 526 (28.8%) in the placebo group had died (odds ratio, 0.95; 95% confidence interval [CI], 0.82 to 1.10; P=0.50). The effect of the trial regimen was similar in six prespecified subgroups. Patients who had been assigned to receive hydrocortisone had faster resolution of shock than those assigned to the placebo group (median duration, 3 days [interquartile range, 2 to 5] vs. 4 days [interquartile range, 2 to 9]; hazard ratio, 1.32; 95% CI, 1.23 to 1.41; P<0.001). Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation than those in the placebo group (median, 6 days [interquartile range, 3 to 18] vs. 7 days [interquartile range, 3 to 24]; hazard ratio, 1.13; 95% CI, 1.05 to 1.22; P<0.001), but taking into account episodes of recurrence of ventilation, there were no significant differences in the number of days alive and free from mechanical ventilation. Fewer patients in the hydrocortisone group than in the placebo group received a blood transfusion (37.0% vs. 41.7%; odds ratio, 0.82; 95% CI, 0.72 to 0.94; P=0.004). There were no significant between-group differences with respect to mortality at 28 days, the rate of recurrence of shock, the number of days alive and out of the ICU, the number of days alive and out of the hospital, the recurrence of mechanical ventilation, the rate of renal-replacement therapy, and the incidence of new-onset bacteremia or fungemia. CONCLUSIONS: Among patients with septic shock undergoing mechanical ventilation, a continuous infusion of hydrocortisone did not result in lower 90-day mortality than placebo. (Funded by the National Health and Medical Research Council of Australia and others; ADRENAL ClinicalTrials.gov number, NCT01448109 .).
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1801
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Cl] Clinical Trial:ClinicalTrial
[St] Status:In-Process
[do] DOI:10.1056/NEJMoa1705835

  3 / 3732 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29371065
[Au] Autor:Morita K; Honda A; Koya J; Toyama K; Ikeda M; Misawa Y; Okugawa S; Nakamura F; Moriya K; Kurokawa M
[Ad] Address:Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
[Ti] Title:Three cases of Candida fermentati fungemia following hematopoietic stem cell transplantation.
[So] Source:J Infect Chemother;, 2018 Jan 19.
[Is] ISSN:1437-7780
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Bloodstream infection with non-Candida albicans Candida species is one of the serious complications among patients with hematological malignancies who receive long-term prophylactic antifungal agents. Here we describe three cases of Candida fermentati (C. fermentati) candidemia after allogeneic stem cell transplantation for hematological malignancies. Case 1 is fluconazole-breakthrough C. fermentati fungemia, which was well controlled with liposomal amphotericin B. Case 2 and 3 were caspofungin-breakthrough C. fermentati fungemia. In case 2, blood culture turned negative for Candida responding to liposomal amphotericin B. Although in vitro susceptibility data for the isolated pathogen suggested the efficacy of both caspofungin and liposomal amphotericin B in all three cases, clinically liposomal amphotericin B seemed to have been more effective for eradication of the pathogen from blood stream. C. fermentati needs to be considered as a possible cause for breakthrough candidemia among post-transplant patients with prolonged antifungal prophylaxis. Discrepancy between in vitro and in vivo susceptibility to antifungals, especially to echinocandins, might provide a clue for the optimal choice of antifungals for C. fermentati infections.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[St] Status:Publisher

  4 / 3732 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29436419
[Au] Autor:Castanheira M
[Ad] Address:JMI Laboratories, North Liberty, IA 52317 mariana-castanheira@jmilabs.com.
[Ti] Title:Fungemia Surveillance in Denmark Demonstrates Emergence of non- , Higher Antifungal Usage and Resistance Rates When Compared to Other Nations.
[So] Source:J Clin Microbiol;, 2018 Feb 07.
[Is] ISSN:1098-660X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Recent changes in the occurrence of fungal species and the difficulties performing reference antifungal susceptibility testing highlight the importance of surveillance of fungal organisms and antifungal resistance rates. Avstad et al. report results from recent fungemia surveillance (2012-2015) in Denmark and compare the results to previous data (2004-2011), showing a decrease in infections accompanied by an increase of and (J Clin Microbiol: 56:2, 2018 doi: 10.1128/JCM.01564-17). Azole resistance among and and echinocandin resistance in was higher in Denmark compared to other regions. Interestingly, the usage of antifungals is higher in Denmark when compared to other Nordic countries.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[St] Status:Publisher

  5 / 3732 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29429866
[Au] Autor:Wang CH; Hsueh PR; Chen FL; Lee WS
[Ad] Address:Department of Laboratory Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
[Ti] Title:Breakthrough fungemia caused by Rhodotorula mucilaginosa during anidulafungin therapy.
[So] Source:J Microbiol Immunol Infect;, 2018 Feb 01.
[Is] ISSN:1995-9133
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1802
[Cu] Class update date: 180212
[Lr] Last revision date:180212
[St] Status:Publisher

  6 / 3732 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29383496
[Au] Autor:Pavic T; Hrabar D; Kralj D; Lerotic I; Ogresta D
[Ad] Address:Department of Gastroenterology and Hepatology, Clinical Hospital Center Sestre Milosrdnice, School of Medicine, University of Zagreb, 10000, Zagreb, Croatia. tajana.pavic@gmail.com.
[Ti] Title:Candidemia after endoscopic therapy with lumen-apposing metal stent for pancreatic walled-off necrosis.
[So] Source:Clin J Gastroenterol;, 2018 Jan 30.
[Is] ISSN:1865-7265
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:Necrotizing pancreatitis remains a challenging and unpredictable condition accompanied by various complications. Endoscopic ultrasound-guided transmural drainage and necrosectomy have become the standard treatment for patients with walled-off necrosis (WON). Endoscopic therapy via lumen-apposing metal stents (LAMS) with large diameters has shown success in the management of pancreatic fluid collections, but there are few data on specific complications of that therapy. We report a case of infected WON and concomitant fungemia following LAMS placement and necrosectomy. In addition, a systematic literature review of current related studies has been provided.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180131
[Lr] Last revision date:180131
[St] Status:Publisher
[do] DOI:10.1007/s12328-018-0823-y

  7 / 3732 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29284316
[Au] Autor:Maubon D; Dard C; Garnaud C; Cornet M
[Ad] Address:a Univsité Grenoble Alpes, CNRS, Grenoble INP*, TIMC-IMAG , Grenoble , France.
[Ti] Title:Profile of GenMark's ePlex® blood culture identification fungal pathogen panel.
[So] Source:Expert Rev Mol Diagn;18(2):119-132, 2018 Feb.
[Is] ISSN:1744-8352
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Fungemia presents high morbi-mortality and thus rapid microbiological diagnosis may contribute to appropriate patient management. In the last decade, kits based on molecular technologies have become available and health care institutes are increasingly facing critical investment choices. Although all these tools aim to achieve rapid fungal detection and species identification, they display different inherent characteristics. Areas covered: Considering technologies allowing detection and identification of fungal species in a sepsis context, the market proposes either tests on positive blood culture or tests on patient's whole blood. In this review, the authors describe and compare the ePlex® Blood Culture Identification Fungal Pathogen (BCID-FP) test, a fully automated one-step single-use cartridge assay that has been designed to detect identify frequent or rare but emerging, fungal species, from positive blood culture. A comparison with the competing kits is provided. Expert commentaries: The ePlex BCID-FP test provides a diversified and rather relevant panel. Its easy-to-use cartridges allow flexible use around the clock. Nevertheless, prospective clinical studies assessing the time-to-result benefit on antifungal stewardship and on hospital length of stay are not available yet. New tools aim to benefit clinicians and patients, but they should be accompanied by supervision of result interpretation and adaptation of antifungal stewardship.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180130
[Lr] Last revision date:180130
[St] Status:In-Data-Review
[do] DOI:10.1080/14737159.2018.1420476

  8 / 3732 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29339278
[Au] Autor:Sandhya M; V A; Maneesha K S; Raja B; R J; S S
[Ad] Address:School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India.
[Ti] Title:Amphotericin B loaded sulfonated chitosan nanoparticles for targeting macrophages to treat intracellular Candida glabrata infections.
[So] Source:Int J Biol Macromol;, 2018 Jan 13.
[Is] ISSN:1879-0003
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:The current study assesses the potential of functionalised chitosan nanoparticles (CNPs) for proficient macrophage delivery of amphotericin B (AmpB) for the management of Candida glabrata fungemia. Chitosan was functionalised by the method of sulfation by using chlorosulfonic acid and the developed compound was confirmed by FTIR, H NMR and degree of sulfation and CHNS analysis. Amphotericin B encapsulated sulfated chitosan (AmpB-SCNPs), when characterized showed a hydrodynamic diameter of 310 ±â€¯14 nm and zeta potential of 41.5 ±â€¯2 mV. The safety of AmpB-SCNPs was established by the alamar cytotoxicity assay in nanoparticle treated macrophages following 24 h incubation. The AmpB-SCNPs showed a significant increase in the reduction of C. glabrata in comparison with the bare AmpB and AmpB-CNPs (55.2 and 42.7 vs 11.12 cfu/ml) indicating that AmpB-SCNPs could be a promising carrier for specific delivery of AmpB to macrophages for effective treatment of Candida glabrata fungemia.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180123
[Lr] Last revision date:180123
[St] Status:Publisher

  9 / 3732 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29266471
[Au] Autor:Nguyen JK; Schlichte MJ; Schady D; Pourciau CY
[Ad] Address:Baylor College of Medicine, Houston, TX, USA.
[Ti] Title:Fatal disseminated Trichosporon asahii fungemia in a child with acute lymphoblastic leukemia and a morbilliform eruption.
[So] Source:Pediatr Dermatol;35(1):e86-e87, 2018 Jan.
[Is] ISSN:1525-1470
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Trichosporonosis is a rare, life-threatening, opportunistic fungal infection that affects immunocompromised individuals with neutropenia, particularly those with underlying hematologic malignancies. We present the case of a 10-year-old boy with acute lymphoblastic leukemia who developed a diffuse, morbilliform eruption in the setting of fever and pancytopenia. He was found to have Trichosporon asahii fungemia with widespread visceral dissemination, and his condition rapidly deteriorated despite treatment. It is important to consider trichosporonosis in the evaluation of a critically ill individual with neutropena and a rash, because the initial cutaneous presentation may appear benign and delayed therapy results in death.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180122
[Lr] Last revision date:180122
[St] Status:In-Process
[do] DOI:10.1111/pde.13359

  10 / 3732 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29345117
[Au] Autor:Osei Sekyere J
[Ad] Address:Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
[Ti] Title:Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen.
[So] Source:Microbiologyopen;, 2018 Jan 18.
[Is] ISSN:2045-8827
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:From 2009, Candida auris has emerged as a multidrug-resistant ascomycete yeast pathogen with the capacity for easy transmission between patients and hospitals, as well as persistence on environmental surfaces. Its association with high mortalities, breakthrough and persistent candidaemia, inconsistencies in susceptibility testing results, misidentification by available commercial identification systems and treatment failure, complicates its management and detection. Within the last nine years, C. auris has been increasingly reported from far-Eastern Asia, the Middle East, Africa, Europe, South and North America with substantial fatalities and misidentification. Herein, I provide a systematic and thorough review of this emerging pathogen. Meta-analysis showed that at least 742 C. auris isolates have been reported in 16 countries, with most of these being from India (≥243), USA (≥232) and UK (≥103) (p-value = .0355) within 2013-2017. Most isolates were from males (64.76%) (p-value = .0329) and blood (67.48%) (p-value < .0001), with substantial crude mortality (29.75%) (p-value = .0488). Affected patients presented with other comorbidities: diabetes (≥52), sepsis (≥48), lung diseases (≥39), kidney diseases (≥32) etc. (p-value < .0001). Resistance to fluconazole (44.29%), amphotericin B (15.46%), voriconazole (12.67%), caspofungin (3.48%) etc. were common (p-value = .0059). Commonly used diagnostic tools included PCR (30.38%), Bruker MALDI-TOF MS (14.00%), Vitek 2 YST ID (11.93%), AFLP (11.55%) and WGS (10.04%) (p-value = .002). Multidrug resistance, high attributable mortality and persistence are associated with C. auris infections. Two novel drugs, SCY-078 and VT-1598, are currently in the pipeline. Contact precautions, strict infection control, periodic surveillance and cleaning with chlorine-based detergents, efficient, faster and cheaper detection tools are necessary for prevention, containment and early diagnosis of C. auris infections.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180118
[Lr] Last revision date:180118
[St] Status:Publisher
[do] DOI:10.1002/mbo3.578


page 1 of 374 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information